SecBot

SecBot
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001861560

NUVL

Nuvalent, Inc.
—
Market cap$9.8B
12-mo target$124.00 (+0.0%)
Insider Selling Cluster (4 insiders)High Impact Filing (8/10)34 New Institutional Positions16 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on NUVL right now — valuation, ownership and activity at a glance.
Market Cap
$9.8B
Cap Size
Mid Cap
Inst. Holders
50 funds
Inst. Value
$4.3B
Inst. Activity
34 buys / 16 sells
SEC Reports
18
Price chart
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 18, 2026 fda_pdufa
PDUFA: NUVL — zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC — 2026-09-18
FDA target action date 2026-09-18 for NUVL (Nuvalent, Inc.). Drug: zidesamtinib. Indication: TKI pre
Jul 27, 2026 SEC
Nuvalent filed a Form 15-12G to terminate its SEC registration under Section 12(g) following the completion of GSK plc's
15-12G — Impact 3/10
Jul 22, 2026 Event
JIDEYTRO
Original Approval — Type 1 - New Molecular Entity — TABLET
Jul 15, 2026 SEC
Nasdaq filed a 25-NSE notification to delist Nuvalent, Inc. shares following the completion of GSK plc's acquisition. Th
25-NSE — Impact 3/10
Jul 15, 2026 SEC
GSK plc has completed its acquisition of Nuvalent, Inc. via a tender offer and merger. The tender offer expired with 91.
8-K — Impact 5/10
Jul 15, 2026 Insider
Srivastava Sapna disposed of 5,146 shares
Director @ $124.00 ($638.1K)
Jul 15, 2026 Insider
Srivastava Sapna disposed of 3,444 shares
Director
Jul 15, 2026 Insider
Srivastava Sapna disposed of 68,500 shares
Director
Analyst ratings buy % -63.5%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
DateFirmActionRatingFirm rating
Jun 24, 2026BernsteinDOWNGRADEMarket Perform 51%
Jun 10, 2026Truist SecuritiesDOWNGRADEHold 55%
Jun 10, 2026TD CowenDOWNGRADEHold 56%
Jun 10, 2026BarclaysDOWNGRADEEqual-Weight 54%
Jun 10, 2026WedbushDOWNGRADENeutral 57%
Jun 10, 2026UBSDOWNGRADENeutral 55%
Jun 10, 2026GuggenheimDOWNGRADENeutral 52%
Jun 9, 2026Wells FargoDOWNGRADEEqual-Weight 54%
Jun 9, 2026HC Wainwright & Co.DOWNGRADENeutral 43%
Jun 9, 2026Cantor FitzgeraldDOWNGRADENeutral 49%
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Jul 1, 202644150035%
Jun 1, 202671610096%
May 1, 202681610096%
Apr 1, 202681510096%
Mar 1, 202681510096%
Feb 1, 202681510096%
Jan 1, 202681510096%
Price targets
Where 9 covering analysts think NUVL trades over the next 12 months.
$124.00 +0.0% upside Hold
Current$123.96 Low$124.00 Median$124.00 High$124.00 9 analysts
$124.00$124.00
Analyst rating Hold· 3.0/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
18 SEC filing reports analyzed · 4 bullish, 4 bearish, 0 mixed, 10 neutral · avg impact 4.6/10.
NEUTRAL15-12G3/10
Nuvalent filed a Form 15-12G to terminate its SEC registration under Section 12(g) following the com
Jul 27, 2026
NEUTRAL25-NSE3/10
Nasdaq filed a 25-NSE notification to delist Nuvalent, Inc. shares following the completion of GSK p
Jul 15, 2026
BULLISH8-K5/10
GSK plc has completed its acquisition of Nuvalent, Inc. via a tender offer and merger. The tender of
Jul 15, 2026
NEUTRALCLUSTER3/10
Three top executives at Nuvalent (CEO, CFO, CDO) sold a combined $7.97M in open-market sales over a
Jul 9, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 18, 2026
fda_pdufa
PDUFA: NUVL — zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC — 2026-09-18
FDA target action date 2026-09-18 for NUVL (Nuvalent, Inc.). Drug: zidesamtinib. Indication: TKI pre-treated advanced ROS1-positive NSCLC. FDA assigne
Aug 6, 2026
earnings_calendar
NUVL Q2 2026 Earnings Scheduled — 2026-08-06
Jul 22, 2026
FDA
JIDEYTRO
Original Approval — Type 1 - New Molecular Entity — TABLET
Jul 16, 2026
listing_status
Delisted: NUVL — removed from the Nasdaq symbol directory
Nuvalent, Inc. - Class A Common Stock
Jul 16, 2026
trading_halt
Halt Resumed: NUVL — trading resumed after D (Security Deletion)
Halted 2026-07-14T23:50:00.000Z | Resumed 2026-07-16T04:00:01.000Z
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$-1.38$-1.48–$-1.130.9%-0.7%0↑ 2↓$0.0B9
Next Q$-1.40$-1.57–$-1.2117.6%-1.0%0↑ 2↓$0.0B9
Current FY$-5.50$-6.37–$-4.695.9%-0.5%1↑ 1↓$0.0B10
Next FY$-4.02$-5.49–$-2.8427.0%+2.8%3↑ 3↓$0.2B10
Current-quarter EPS estimate — revision history
WhenEPS estimateChange vs now
Current$-1.378—
7d ago$-1.368-0.010
30d ago$-1.368-0.010
60d ago$-1.376-0.002
90d ago$-1.372-0.006
Institutional ownership
Which big funds own NUVL (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $4.3B total value (35,135,383 shares) as of 2026-Q2. Top holders: BlackRock,, FIL, VANGUARD. Net buying activity: 34 institutions added/increased vs 16 reduced.
Top holders — 2026-Q2
FundSharesValue% TrackedLast move
BlackRock, Inc.5,585,619$689.8M15.9%—
FIL Ltd2,946,506$363.9M8.4%DOUBLED +4532986.2%
VANGUARD PORTFOLIO MANAGEMENT LLC2,589,282$319.8M7.4%—
VANGUARD CAPITAL MANAGEMENT LLC2,459,118$303.7M7.0%—
STATE STREET CORP2,091,044$258.2M6.0%—
GOLDMAN SACHS GROUP INC1,640,833$202.6M4.7%DOUBLED +205.5%
FMR LLC1,417,590$175.1M4.0%NEAR_EXIT -84.7%
GEODE CAPITAL MANAGEMENT, LLC1,407,353$173.8M4.0%—
BARCLAYS PLC1,268,265$156.6M3.6%DOUBLED +4011.9%
RA CAPITAL MANAGEMENT, L.P.1,246,456$153.9M3.5%TRIM -50.8%
Recent position changes
FundActionPrevCurrentChangeValue
FIL LtdDOUBLED652,946,506+4532986.2%$363.9M
GOLDMAN SACHS GROUP INCDOUBLED537,1581,640,833+205.5%$202.6M
FMR LLCNEAR_EXIT9,274,9591,417,590-84.7%$175.1M
BARCLAYS PLCDOUBLED30,8441,268,265+4011.9%$156.6M
RA CAPITAL MANAGEMENT, L.P.TRIM2,534,1451,246,456-50.8%$153.9M
Pentwater Capital Management LPNEW—1,175,000—$145.1M
BALYASNY ASSET MANAGEMENT L.P.NEW—1,037,583—$128.1M
BANK OF AMERICA CORP /DE/DOUBLED216,516876,830+305.0%$108.3M
MORGAN STANLEYDOUBLED200,790681,225+239.3%$84.1M
WESTFIELD CAPITAL MANAGEMENT CO LPNEW—585,583—$72.3M
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
8 insiders, 50 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
DateInsiderTitleTypeSharesPriceValue
Jul 15, 2026Srivastava SapnaDirectorU5,146$124.00$638.1K
Jul 15, 2026Srivastava SapnaDirectorD3,444——
Jul 15, 2026Srivastava SapnaDirectorD68,500——
Jul 15, 2026Srivastava SapnaDirectorD20,000——
Jul 15, 2026Srivastava SapnaDirectorD15,000——
Jul 15, 2026Srivastava SapnaDirectorD3,789——
Jul 15, 2026Srivastava SapnaDirectorD4,147——
Jul 15, 2026Balcom AlexandraChief Financial OfficerAWARD14,350——
Jul 15, 2026Balcom AlexandraChief Financial OfficerU44,433$124.00$5.5M
Jul 15, 2026Balcom AlexandraChief Financial OfficerD33,646——
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for NUVL.
Shares short
715,798
Settlement Jul 15, 2026
Change vs prior
-75.4%
Semi-monthly cycle
Days to cover
1.0
At avg daily volume
Of shares outstanding
≈0.9%
Estimate — not % of float
HaltedCodeReasonStatus
Jul 14, 2026T12Info RequestedNot resumed
Jul 14, 2026DDeletionResumed
All NUVL filing & press-release reports (18)